Contrast media: Procedural capacities and potential risks

Reviews in Cardiovascular Medicine

Volumn 9, Issue SUPPL. 1, 2008, Pages

  Davidson, Charles J ^a   Erdogan, Ata K ^a  

^a NONE

Author keywords

Computerized tomography; Contrast media; Contrast nephropathy

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ANTIOXIDANT; ASCORBIC ACID; BICARBONATE; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIPHENHYDRAMINE; DOPAMINE; FENOLDOPAM; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSAL; IOXAGLIC ACID; MANNITOL; MEGLUMINE DIATRIZOATE; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; PROSTAGLANDIN E1; SODIUM CHLORIDE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANGIONEUROTIC EDEMA; BLOOD PRESSURE; BRADYCARDIA; BRONCHOSPASM; CARDIOTOXICITY; CHEMICAL STRUCTURE; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; CRYSTALLOID; DISEASE ASSOCIATION; DIURESIS; DRUG EFFECT; DRUG EFFICACY; EDEMA; ELECTROLYTE BALANCE; ELECTROPHYSIOLOGY; EMBOLISM; FEVER; FOOD ALLERGY; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART RATE; HEART STROKE VOLUME; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEAT SENSATION; HEMODYNAMICS; HEMOFILTRATION; HUMAN; HYDRATION; HYPERSENSITIVITY; HYPERTENSION; HYPOTENSION; IMAGE QUALITY; INCIDENCE; INJECTION PAIN; KIDNEY INJURY; LARYNX SPASM; LUNG EDEMA; META ANALYSIS; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSMOLALITY; PATIENT ASSESSMENT; PATIENT SAFETY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; RISK FACTOR; SHELLFISH; SHOCK; SIDE EFFECT; SKIN MANIFESTATION; SNEEZING; STROKE; SYSTEMATIC REVIEW; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; URTICARIA; VASODILATATION; VERTIGO; VOMITING;

ACUTE DISEASE; BLOOD PRESSURE; CONTRAST MEDIA; HEART RATE; HEMODYNAMICS; HUMANS; INCIDENCE; KIDNEY DISEASES; OSMOLAR CONCENTRATION; RISK ASSESSMENT; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 42249091731     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Christiansen C. X-ray contrast media: an overview. Toxicology. 2005;209:185-187.
2. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: A clinical and evidence-based approach. Circulation. 2006;113:1799-1806.
3. Dawson P. Cardiovascular effects of contrast agents. Am J Cardiol. 1989;64:2E-9E.
4. Dunkel JA, Bokenes J, Karlsson JO, Refsum H. Cardiac effects of iodixanol compared to those of other nonionic and ionic contrast media on the isolated rat heart. Acta Radiol. 1995;399(suppl):142-154.
5. Hirshfeld JW, Wieland J, Davis CA, et al. Hemodynamic and electrocardiographic effects of ioversal during cardiac angiography. Comparison with iopamidol and diatrizoate. Invest Radiol. 1989;24:138-144.
6. Bergstra A, van Dijk RB, Brekke O, et al. Hemodynamic effects of iohexol during ventriculography in patients with compromised left ventricular function. Cathet Cardiovasc Intervent. 2000;50:314-321.
7. Giesler T, Baum U, Ropers D, et al. Noninvasive visualization of coronary arteries using contrast-enhanced multidetector CT: Influence of heart rate on image quality and stenosis detection. AJR Am J Roentgenol. 2002;179:911-916.
8. Hoffmann MH, Shi H, Manzke R, et al. Noninvasive coronary angiography with 16-detector row CT: effect of heart rate. Radiology. 2005;234:86-97.
9. Leschka S, Wildermuth S, Boehm T, et al. Noninvasive coronary angiography with 64-section CT: Effect of average heart rate and heart rate variability on image quality. Radiology. 2006;241:378-385.
10. Tveit K, Bolz KD, Bolstad B, et al. Iodixanol in cardioangiography: A double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml. Acta Radiologica. 1994;35:614-618.
11. Manninen H, Tahvanainen K, Borch KW, et al. Iodixanol, a new non-ionic, dimeric contrast medium in cardioangiography: A double-masked, parallel comparison with iopromide. Eur Radiol. 1995;5:364-370.
12. Schmid I, Didier D, Pfammatter T, et al. Effects of non-ionic iodinated contrast media on patient heart rate and pressures during intra-cardiac or intra-arterial injection. Int J Cardiol. 2007;118:389-396.
13. Murphy G, Campbell DR, Fraser DB. Pain in peripheral arteriography: an assessment of conventional versus ionic and non-ionic low-osmolality contrast agents. J Can Assoc Radiol. 1988;39:103-106.
14. Pugh ND, Sissons GR, Ruttley MS, et al. Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide. Clin Radiol. 1993;47:96-99.
15. Justesen P, Downes M, Grynne BH, et al. Injection-associated pain in femoral arteriography: a European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide. Cardiovasc Intervent Radiol. 1997;20:251-256.
16. Manke C, Marcus C, Page A, et al. Pain in femoral arteriography: a double-blind, randomized, clinical study comparing safety and efficacy of the iso-osmolar iodixanol 270 mg I/ml and the low-osmolar iomeprol 300 mg I/ml in 9 European centers. Acta Radiologica. 2003;44: 590-596.
17. Snyder C, Cramer R, Amplatz K. Isolation of sodium as a cause of ventricular fibrillation. Invest Radiol. 1971;6:245-248.
18. Chai CM, Almen T, Baath L, Besjakov J. Adding sodium and calcium ions to the contrast medium iodixanol reduced the risk of ventricular fibrillation during perfusion of the left coronary artery in pigs: effects of electrolytes, viscosity, and chemotoxicity of an isotonic perfusate. Acad Radiol. 2004;11:583-593.
19. Davidson CJ, Mark DB, Pieper KS et al. Thrombotic and cardiovascular complications related to nonionic contrast media during cardiac catheterization: analysis of 8,517 patients. Am J Cardiol. 1990;65:1481-1484.
20. Schrader R, Esch I, Ensslen R, et al. A randomized trial comparing the impact of nonionic (iomeprol) versus an ionic (ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after angioplasty. J Am Coll Cardiol. 1999;33:395-402.
21. Davidson CJ, Laskey WK, Hermiller JB, et al. Randomized trial of contrast media utilization in high-risk PTCA: The COURT trial. Circulation. 2000;101:2172-2177.
22. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol. 2001;176:1385-1388.
23. Cohan RH, Matsumoto JS, Quagliano PV. American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. 5th ed. Reston, VA: American College of Radiology; 2004:5-77.
24. Sutton AG, Finn P, Grech ED, et al. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. Am Heart J. 2001;141:677-683.
25. Huang SW. Seafood and iodine: an analysis of a medical myth. Allergy Asthma Proc. 2005;26:468-469.
26. Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol. 1991;87:867-872.
27. Lasser EC, Berry CC, Talner LB, et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med. 1987;317:845-849.
28. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high and low-osmolality iodinated contrast media. Radiology. 1993;188:171-178.
29. Davidson CJ, Hlatky M, Morris KG et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med. 1989;110:119-124.
30. Bartholomew BA, Harjai KJ, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004;93:1515-1519.
31. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39:930-936.
32. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial (the Iohexol Cooperative Study). Kidney Int. 1995;47:254-261.
33. Brosius FC, Hostetter TH, Kelepouris E, et al. AHA science advisory. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease. Circulation. 2006;114:1083-1087.
34. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499.
35. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) Study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115:3189-3196.
36. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48:692-699.
37. Verow P, Nossen JO, Sheppick A, Kjaersgaard P. A comparison of iodixanol with iopamidol in aorto-femoral angiography. Br J Radiol. 1995;68:973-978.
38. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2007;50:1-157.
39. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
40. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. JAMA. 2004;291:2328-2334.
41. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211-1217.
42. Stacul F, Adam A, Becker C, Davidson CJ, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol. 2006;98(suppl):59K- 77K.
43. Schweiger MJ, Chambers CE, Davidson CJ, et al. Prevention of contrast-induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv. 2007;69:135-140.
44. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant. 2004;19:2747-2753.
45. Spargias K, Alexopoulos E, Kyrzopoulos S. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837-2842.
46. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117:938-947.
47. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773-2782.
48. Marenzi G, Marana I, Lauri G, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-1340.
49. Davidson C, Stacul F, McCullough PA, et al. Contrast medium use. Am J Cardiol. 2006;98(6A):42K-58K.